What actually changed when the shortages ended
During a declared shortage, compounding pharmacies may prepare copies of the scarce drug. When the FDA removes a drug from the shortage list, that permission collapses back to the baseline rules: traditional (503A) pharmacies may not regularly compound what amounts to a copy of a commercially available drug, and the agency reiterated in 2026 that it had not identified a clinical need supporting bulk compounding of these molecules by outsourcing facilities, proposing to keep semaglutide and tirzepatide off the 503B bulks list.
The surviving lawful basis for a compounded GLP-1 is a documented, patient-specific clinical difference: a formulation change a prescriber determines this patient needs, which the FDA-approved product can't provide. What explicitly does not qualify: price, convenience, or supply preference. A program whose real pitch is 'the same drug, cheaper' is built on the argument the FDA has already rejected.
Post-shortage, the question isn't 'can we compound it?' It's 'can this prescriber document why this patient needs this formulation instead of the approved product?' If the honest answer is price, the model needs rework, not better copy.
The claims that are off the table
Certification reviewers and ad platforms converge on the same claim rules for compounded GLP-1s, and they're stricter than most weight-loss marketing assumes:
- No equivalence: 'generic Ozempic', 'same as Zepbound', 'identical to the brand': compounded preparations are not generics and may not be marketed as replacements for FDA-approved drugs.
- No implied approval: 'FDA-approved compounded semaglutide' is a contradiction; the approved drugs are approved, your compounded formulation is not, and every selling surface should say so.
- No borrowed trial numbers: the headline results from brand-name clinical trials belong to the products those trials studied. '21% weight loss' tiles selling a compounded formulation the trial never touched are a flagship finding.
- No outcome guarantees or typical-case testimonials that aren't typical: quantified promises need substantiation for the product actually sold, and testimonial rules follow FTC endorsement guidance.
- Brand names used nominatively (to truthfully say what a product is not, or in editorial content) are workable; brand names used to borrow identity are not.
What a compliant compounded program looks like
The programs that survive scrutiny share a shape. The clinical rationale is documented at the prescriber level: the medical group can articulate, per patient, why the compounded formulation over the approved product, and the marketing is built downstream of that rationale rather than in place of it. Compounded status is disclosed on every surface that sells: not FDA-approved, prescribed at a licensed clinician's discretion, not all patients qualify.
Additives deserve particular honesty. Formulations with vitamins or other adjuncts are common, and an additive can be part of a legitimate clinical rationale, but marketing that presents the additive as a convenience perk while relying on it as the legal basis for compounding is the exact pattern that draws review. Say what the formulation is for, clinically, or don't build on it.
And the supply chain has to hold: a named pharmacy relationship (503A patient-specific or 503B, understood and documented), batch-testing claims you can evidence, and no impermissible research chemicals sharing a catalog with your prescription products; peptide gray-market adjacency is a certification barrier all by itself.
How reviewers read a weight-loss site in 2026
Assume the reviewer opens your site with three questions. Is a real clinician deciding? (Intake before payment, a decline path, provider-may-decline disclosure.) Is the compounded status honest? (Disclosure on every selling surface, no equivalence framing, no borrowed numbers, including in image tiles and page metadata, which text-only reviews miss and thorough ones don't.) And does the model still make sense post-shortage? (A clinical-need story that isn't 'cheaper'.)
Weight-loss sites also carry the heaviest advertising exposure: before/after imagery, transformation testimonials, and speed claims are the top flag categories on every major ad platform, certification or not. Certification gets you into the auction; the claims discipline keeps you there.
If you want the reviewer's read before the reviewer's invoice, our free Preflight scanner runs a site against these patterns (equivalence language, missing disclosures, borrowed-number tiles it can see, tracker placement, payment fingerprints) and flags the judgment calls (like your clinical-need documentation) that no scanner should pretend to grade.
Where Embed Care fits
Embed Care operates the clinical and pharmacy infrastructure behind partner-branded telehealth programs, including GLP-1 care lines, with the compounding posture, disclosures, and claims discipline built in, informed by running certified brands of our own. Partners bring an audience; the program underneath arrives certification-ready, and every storefront passes a Preflight scan before launch.
If your current program grew up during the shortage and hasn't been re-underwritten since, that review is overdue; book a LegitScript guidance call and bring your product page.
Frequently asked
- Are compounded GLP-1s illegal now?
- No, but the basis narrowed. With the shortages resolved, routine copies of the approved drugs are off the table for traditional compounders; what remains is patient-specific compounding backed by a documented clinical need the approved product can't meet. Price and convenience don't qualify.
- Can I say my compounded semaglutide contains 'the same active ingredient' as the brand?
- It's risky phrasing. Even where technically accurate, active-ingredient comparisons read as equivalence claims unless surrounded by clear non-equivalence context ('not a generic, not interchangeable, not FDA-approved'). Many operators simply avoid the construction.
- Do the restrictions apply to marketing or to the compounding itself?
- Both, from different regulators. The FDA's essentially-a-copy rules govern what pharmacies may prepare; FTC substantiation rules and certification standards govern what you may claim; ad platforms add their own layer. A compliant program clears all three.
- My program launched during the shortage. What should I re-check first?
- Three things, in order: the clinical-need documentation behind current prescribing, the claims on every selling surface (including image tiles and meta descriptions), and your pharmacy's post-shortage posture. A readiness scan is a fast first pass on the middle one.
Want pricing for your program, and the Rx menu that goes with this?
We scope both on a call: 20 minutes with the partnerships team, no prep, no obligation.
Book a demo